SCHEMBL2962767

SCHEMBL2962767

CC(=O)Nc1ccc(COc2cc(N)cc(Cl)c2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.52
MEN1 O00255 5/20 0.52
MAPT P10636 3/20 0.51
NPSR1 Q6W5P4 1/20 0.51
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.46
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
MAPK1 P28482 1/20 0.45
TDP1 Q9NUW8 2/20 0.45
RORC P51449 1/20 0.45
LMNA P02545 2/20 0.44
CYP1A2 P05177 1/20 0.44
TP53 P04637 1/20 0.44
POLB P06746 1/20 0.44
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
MAOA P21397 2/20 0.44
MAOB P27338 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4639017 0.82 MEN1 (0.61) KMT2AMEN1NPC1RAB9AL3MBTL1
SCHEMBL10440232 0.82 RXRA (0.63) KMT2AMEN1MAPTNPSR1NPC1
SCHEMBL2968318 0.81 LMNA (0.64) KMT2AMEN1MAPTSMN1; SMN2TDP1
SCHEMBL10597979 0.81 KMT2A (0.66) KMT2AMEN1MAPTNPSR1NPC1
SCHEMBL2957654 0.81 MAPT (0.54) KMT2AMEN1MAPTNPSR1HTT
SCHEMBL2962789 0.80 MRGPRX4 (0.49) KMT2AMEN1MAPTNPC1RAB9A
SCHEMBL21477287 0.75 MAOB (0.60) MAOAMAOB
SCHEMBL2969885 0.75 MAOB (0.50) NPC1RAB9AHTTSMN1; SMN2MAOA
SCHEMBL31530135 0.75 MEN1 (0.66) KMT2AMEN1MAPTNPC1RAB9A
SCHEMBL15903046 0.74 MAOB (0.62) KMT2AMEN1MAPTRAB9AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338605-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2012-12-25 US disclosed
US-20100256139-A1 Anti-Viral Compounds ABBOTT LABORATORIES (US) 2010-10-07 US disclosed
EP-1979349-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2010-07-28 EP disclosed
US-7763731-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2010-07-27 US disclosed
CN-101384592-A Antiviral compounds ABBOTT LAB (US) 2009-03-11 CN disclosed
EP-1979349-A2 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-10-15 EP disclosed
US-20070232645-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed
WO-2007076035-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232645-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 KMT2A 3566/4885MEN1 4571/4885MAPT 1347/4885
US-20100256139-A1 Anti-Viral Compounds HAVCR2, MAVS, EIF2AK2 KMT2A 3566/4885MEN1 4571/4885MAPT 1347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.